Analyst Price Target is $9.33
▲ +133.92% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for G1 Therapeutics in the last 3 months. The average price target is $9.33, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 133.92% upside from the last price of $3.99.
Current Consensus is
Moderate Buy
The current consensus among 4 investment analysts is to moderate buy stock in G1 Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Read More
